Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMPHOTEC vs ECOZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Not extensively metabolized; minimal systemic absorption after topical application.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
>95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 89–93% bound to plasma proteins, primarily albumin.
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
None
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
Known hypersensitivity to imidazole antifungals or any component of the formulation
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMPHOTEC vs ECOZA, answered by our medical review team.
AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMPHOTEC and ECOZA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMPHOTEC and ECOZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.